Legend Biotech Corporation (NASDAQ: LEGN) is a clinical and commercial-stage biotechnology company focused on cellular therapies, including CAR-T for hematologic cancers. The company’s lead product, Carvykti (cilta-cel), is approved for relapsed multiple myeloma and developed in partnership with Janssen. Legend combines deep cell therapy expertise with a broad pipeline of next-gen immunotherapies. It offers investors high-potential exposure to commercial-stage oncology innovation and cell-based treatment breakthroughs.
Derniers articles sur les actions